Search

A recent report from the National University of Singapore discusses the impact of gestational diabetes mellitus (GDM) on the development of non-alcoholic fatty liver disease (NAFLD) in both mothers and offspring. The study analyzed data from 20 studies and found that mothers with a history of GDM had a 50% increased risk of developing NAFLD, while offspring born to GDM-complicated pregnancies had a two-fold elevated risk of NAFLD development. The findings highlight the importance of early monitoring and intervention for NAFLD in both generations from GDM-complicated pregnancies. [Extracted from the article]

A recent report from Hunan University of Chinese Medicine explores the treatment of non-alcoholic fatty liver disease (NAFLD) based on dietary factors. The researchers highlight the importance of dietary components, such as fructose, protein, and vitamins, in the progression or prevention of NAFLD. They also discuss the Mediterranean dietary pattern and compare the effectiveness of low-fat and low-carbohydrate diets in preventing the development of NAFLD. The study emphasizes the role of dietary factors in the prevention and treatment of NAFLD, as there are currently no specific drugs available for this condition. [Extracted from the article]

A recent study conducted by researchers at Ahvaz Jundishapur University of Medical Sciences in Iran examined the relationship between non-alcoholic fatty liver disease (NAFLD) and cholecystectomy, a surgical procedure to remove the gallbladder. The study found that patients with NAFLD who had a history of cholecystectomy had significantly higher levels of liver fibrosis compared to those without a history of the procedure. The researchers also noted a positive correlation between body mass index (BMI) and liver fibrosis in the group of patients with a history of cholecystectomy. This study provides valuable insights into the potential risk factors and complications associated with NAFLD and cholecystectomy. [Extracted from the article]

A recent systematic review and meta-analysis conducted by investigators from Southeast University in China examined the association between platelet indices and non-alcoholic fatty liver disease (NAFLD). The study analyzed 19 publications involving 3,592 NAFLD patients and 1,194 healthy individuals. The results showed that NAFLD patients had lower platelet count but higher mean platelet volume and platelet distribution width compared to healthy controls. Additionally, patients with non-alcoholic steatohepatitis (NASH) had lower platelet count and higher mean platelet volume than non-NASH individuals. The study suggests that a higher mean platelet volume is associated with lipid metabolic disorders in NAFLD. [Extracted from the article]

This document provides information about a research study that aims to investigate the effects of different nutrition programs on individuals with non-alcoholic fatty liver disease (NAFLD). The study will include participants who are 18-64 years old and have a body mass index (BMI) between 25-40 kg/m2. The study will compare the effects of a low-fat diet, a low-fat diet supplemented with aronia juice, and a Mediterranean diet, both with and without aronia juice supplementation. The study is not yet recruiting participants and is estimated to be completed by June 15, 2026. The primary contact for the study is Gamze Akbulut at Istanbul Kent University. [Extracted from the article]

A recent study conducted by researchers at Iran University for Medical Sciences investigated the effects of saffron supplementation on patients with non-alcoholic fatty liver disease (NAFLD). The study involved 76 NAFLD patients who were given a weight loss diet and physical activity program, and were randomly assigned to receive either a saffron-coated tablet or a placebo tablet for 12 weeks. The results showed that saffron supplementation led to a reduction in liver steatosis score, steatosis percent, steatosis stage, total cholesterol, triacylglycerol, low-density lipoprotein, and fasting blood sugar compared to the placebo. However, there was no significant difference in liver fibrosis, aminotransferase, gamma-glutamyltransferase, insulin, insulin resistance, and blood pressure between the two groups. The researchers concluded that saffron may have beneficial effects that require further investigation in future clinical trials. [Extracted from the article]

A systematic review conducted by researchers from Aarhus University Hospital in Denmark explores the relationship between non-alcoholic fatty liver disease (NAFLD) and brain dysfunction. The review analyzes preclinical evidence from animal models of NAFLD and identifies neurobiological changes in areas such as neuroinflammation, neurodegeneration, neurotransmitter alterations, oxidative stress, and changes in proteins and synaptic density. The findings suggest that there is an association between all stages of NAFLD and neurobiological changes in preclinical models. This research provides valuable insights into the comorbidity of NAFLD and cognitive impairment, which can impact patients' quality of life. [Extracted from the article]

A recent study conducted by researchers at Zhejiang University School of Medicine explored the potential association between gastroesophageal reflux disease (GERD) and non-alcoholic fatty liver disease (NAFLD). The study utilized Mendelian randomization (MR) to analyze the causal relationship between the two diseases. The researchers found evidence of a causal relationship between GERD and NAFLD through MR and meta-analysis. This study provides valuable insights into the connection between these two conditions. [Extracted from the article]

A study conducted by researchers at Weill Cornell Medicine in New York City aimed to understand the prevalence and nature of cognitive deficits in individuals with non-alcoholic fatty liver disease (NAFLD) and whether liver fibrosis is associated with worse cognitive performance. The study included 69 participants with NAFLD, and cognitive deficits were found to be common in this population. Liver fibrosis was modestly associated with worse inhibitory control and attention. This research provides valuable insights into the cognitive impairments associated with NAFLD and highlights the importance of liver fibrosis assessment in understanding cognitive performance in individuals with NAFLD. [Extracted from the article]

A recent study conducted at SRM Medical College Hospital and Research Centre examined the association between insulin resistance and non-alcoholic fatty liver disease (NAFLD) in lean and obese individuals. The study found that insulin resistance, a key factor in metabolic syndrome, is prevalent in lean individuals with NAFLD and plays a significant role in its development. The research also revealed that insulin resistance is correlated with weight gain in NAFLD patients. These findings highlight the importance of understanding the metabolic profile and insulin resistance in individuals with NAFLD, regardless of their body weight. [Extracted from the article]

A recent study compared the clinical profiles and outcomes of non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD). The study found that NAFLD and MASLD are similar, with individuals with MASLD being slightly older and having a slightly higher mortality risk due to cardiometabolic risk factors. The study concluded that the terms NAFLD and MASLD can be used interchangeably, but further consideration is needed for the small proportion of patients with NAFLD who do not meet MASLD criteria. [Extracted from the article]

A study conducted at Zhejiang University in Hangzhou, China, investigated the effects of combining Exenatide and Metformin on patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease. The study included 128 patients who were randomly assigned to either Group A (receiving Metformin) or Group B (receiving Exenatide injection and Metformin). After 24 weeks of treatment, Group B showed lower levels of fasting blood glucose, postprandial glucose, triglycerides, total cholesterol, alanine aminotransferase, and aspartate aminotransferase compared to Group A. Additionally, Group B had lower counts of Escherichia coli and Enterococcus faecalis, and higher counts of Bifidobacteria and Lactobacillus. The researchers concluded that the combination of Exenatide and Metformin may have synergistic effects in improving metabolic and hepatic parameters, as well as regulating intestinal flora, providing a promising therapeutic option for these patients. [Extracted from the article]

A study conducted by Dong-A University College of Medicine in South Korea compared the accuracy of non-invasive tests (NITs) for diagnosing fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). The study found that acoustic radiation force impulse (ARFI) had the highest diagnostic value among the NITs tested. ARFI was not affected by various factors and maintained diagnostic accuracy compared to serum NITs. The researchers recommend ARFI as a valuable diagnostic test for screening advanced fibrosis in patients with NAFLD. [Extracted from the article]

A new study from University Ziekenhuis Brussel has found that the prevalence and incidence of non-alcoholic fatty liver disease (NAFLD) is increasing due to the obesity pandemic caused by the availability of ultra-processed foods and decreased physical activity. Factors such as socioeconomic status, ethnicity, and geographical location are associated with NAFLD, with lower socioeconomic status correlating with higher incidence. The study emphasizes the importance of lifestyle adjustments and patient empowerment in managing NAFLD, as there is no hard medical treatment available. Additionally, the study highlights the potential for teleconsulting to provide ambulatory follow-up for NAFLD patients, reducing the carbon footprint. [Extracted from the article]

A recent study conducted by researchers at Shanxi University in China has found that polyphenols from foxtail millet may improve non-alcoholic fatty liver disease (NAFLD) by regulating the intestinal microbiome in mice. NAFLD is a common chronic liver disease associated with metabolic dysfunction, and effective interventions are currently lacking. The study showed that bound polyphenols from foxtail millet were able to restore the gut microbiota in mice with NAFLD induced by a high-fat diet. The findings suggest that polyphenols from foxtail millet may have protective effects against NAFLD. [Extracted from the article]

A new report discusses research findings on non-alcoholic fatty liver disease (NAFLD) in children and adolescents. The study aimed to explore the relationship between arm circumference (AC) and NAFLD in American children and adolescents. The researchers used data from the National Health and Nutrition Examination Survey (NHANES) and found that AC was positively correlated with the risk of NAFLD and liver steatosis. They also identified a non-linear relationship and saturation effect between AC and NAFLD risk, with an inflection point at 34.5 cm. The study concludes that AC is independently correlated with an increased risk of NAFLD and the severity of liver steatosis in American children and adolescents. [Extracted from the article]

A study conducted by the University of West Attica in Athens, Greece, explores the prevalence of non-alcoholic fatty liver disease (NAFLD) in women. The researchers found that NAFLD is common in up to 30% of the global adult female population. Factors such as age, obesity, and metabolic syndrome have been linked to NAFLD in women. The study suggests that personalized management approaches for women with NAFLD should consider risk profile, hormonal status, age, and metabolic components. Further research is needed to understand how gender affects biomarkers and to develop sex-specific prediction models for NAFLD. [Extracted from the article]

A recent study conducted by researchers at the University of Jaffna examined the relationship between lipid profile, insulin resistance, and non-alcoholic fatty liver disease (NAFLD) among type 2 diabetes patients receiving treatment in Jaffna. The study found that a significant number of patients exhibited insulin resistance (70.5%) and NAFLD (77.7%), with a majority also having comorbid dyslipidemia (51.7%). The researchers concluded that understanding this complex interplay is crucial for better patient outcomes and called for larger clinical studies to validate their findings. The full study can be accessed for free through the provided link. [Extracted from the article]

A recent study conducted at the University of Texas Austin examined the effects of dietary interventions on peripheral and cerebral vascular function in individuals with non-alcoholic fatty liver disease (NAFLD). The study included 30 middle-aged adults with NAFLD or with elevated NAFLD risk. Participants were randomly assigned to either a low-carbohydrate diet or a low-calorie diet for two weeks. The results showed that both dietary interventions led to significant reductions in body weight, fat mass, and liver fat content. Additionally, there were improvements in peripheral arterial stiffness and endothelium-dependent vasodilation. The study suggests that dietary interventions can have positive effects on vascular function in individuals with NAFLD. [Extracted from the article]

Researchers at Gonabad University of Medical Sciences conducted a study comparing the effects of nano-silymarin and silymarin on non-alcoholic fatty liver in rats. The study found that both nano-silymarin and silymarin were effective in reducing serum triglyceride levels compared to a negative control group. However, the reduction of cholesterol, LDL-C, AST, and ALT by nano-silymarin was not significant compared to silymarin. The study concluded that nano-silymarin could be used to prevent non-alcoholic fatty liver disease. [Extracted from the article]

A recent study conducted at Guizhou University of Traditional Chinese Medicine in Guiyang, China, investigated the effects of Gehua Jiejiu Dizhi decoction (GJDD) on alcoholic fatty liver disease (AFLD) in mice. The study found that GJDD reduced fat deposition in the liver tissue and modulated protein expression related to lipid metabolism, bile acid metabolism, and antioxidant stress. The research used proteomic methods to identify and quantify differentially expressed proteins in the liver tissue of mice. These findings provide evidence for the potential therapeutic effects of GJDD in treating AFLD. [Extracted from the article]

A recent study conducted in Catanzaro, Italy, examined the gut microbiota composition in patients with Inflammatory Bowel Disease (IBD) and Non-Alcoholic Fatty Liver Disease (NAFLD). The study found that gut microbiota imbalances play a significant role in the development of both IBD and NAFLD. The researchers compared the gut microbial composition in patients with IBD, NAFLD, or a combination of both, as well as healthy controls. The study identified specific bacterial differences between the groups, suggesting a potential microbial signature influenced by gut inflammation. This research provides new insights into the relationship between gut microbiota and these diseases. [Extracted from the article]

A recent study conducted at Peking University First Hospital in Beijing, China, explored the role of probiotics in the gut microbiome and metabolome of mice with non-alcoholic fatty liver disease (NAFLD). The researchers compared the effects of two probiotics, Akkermansia muciniphila and VSL#3, on NAFLD mice. They found that both probiotics reduced hepatic fat content, but A. muciniphila was more effective. Additionally, probiotic treatment restored the diversity of gut flora and improved metabolism in the mice. These findings suggest that probiotics may have potential as a treatment for NAFLD. [Extracted from the article]

A recent study conducted at Shiraz University of Medical Sciences in Iran aimed to assess the effect of sumac supplement on overweight or obese patients with non-alcoholic fatty liver disease (NAFLD). The study involved 45 NAFLD patients who were randomly divided into two groups: one group received sumac capsules with a balanced diet, while the other group received a placebo with a balanced diet. The results showed a significant decrease in anthropometric indices and biochemical levels in both groups after the intervention. However, no significant difference was observed between the two groups. The researchers recommend further studies with larger sample sizes to be conducted on this issue. [Extracted from the article]

The University of California has been issued a patent for the use of bile acids in disease treatment. The patent describes the impact of the microbiome on the chemistry of an entire mammal, specifically focusing on the amino acid conjugations of host bile acids. These bile acid conjugates are found in humans and are enriched in states of disease. The patent provides methods of treating subjects with various diseases, including inflammatory bowel disease, liver cancer, and atherosclerosis, by administering pharmaceutical compositions that modulate levels of bile acid conjugates. [Extracted from the article]

A recent study conducted by investigators from Sichuan University in Chengdu, China, explores the relationship between childhood obesity and metabolic disorders such as diabetes and non-alcoholic fatty liver disease (NAFLD). The researchers found that obesity in children can lead to weight gain and increase the risk of these related illnesses. They also discovered that obesity disrupts immune system function, causing inflammation and the development of pediatric obesity and its associated disorders. The study emphasizes the importance of considering immune system components as a preventive and therapeutic approach to childhood obesity-related diseases. [Extracted from the article]

A study conducted by researchers at the Chinese University of Hong Kong explores the relationship between non-alcoholic fatty liver disease (NAFLD) and erythropoietin (EPO) hyporesponsiveness. The researchers hypothesized that NAFLD may be a risk factor for EPO hyporesponsiveness due to iron deficiency and inflammation. The study found that rats with NAFLD had a lower erythroid response to EPO treatment compared to healthy rats, and this was attributed to functional iron deficiency associated with inflammation. The research suggests that NAFLD could impact EPO responsiveness. [Extracted from the article]

A recent study conducted by researchers at Hacettepe University in Ankara, Turkey, explored the effects of a low-fat diet on individuals with obesity/overweight and non-alcoholic fatty liver disease (NAFLD). The study involved 108 participants who followed a 12-week weight loss program with randomly prescribed low-fat diets. The results showed significant reductions in body weight, body mass index, body fat percentage, and waist, hip, and neck circumferences. Additionally, there were significant improvements in biochemical parameters and inflammatory markers. The findings suggest that a low-fat diet can lead to improvements in both anthropometric measurements and biochemical parameters in individuals with obesity/overweight and NAFLD. [Extracted from the article]

A new report from researchers at the Medical University of Lublin in Poland discusses the findings on non-alcoholic fatty liver disease (NAFLD). The report highlights the importance of considering an unbalanced diet and imbalanced nutritional status as potential causes of NAFLD, in addition to well-known factors such as obesity and diabetes. The researchers summarize the current knowledge on the micro- and macronutrient status of NAFLD patients and suggest that supplementation of certain vitamins and elements, such as vitamin A, B complex, C, D, and zinc, may alleviate symptoms. However, further research is needed to determine the appropriate dosages for supplementation. [Extracted from the article]

A recent study conducted by researchers at Yasuj University of Medical Sciences in Iran explored the association between dietary polyphenols and the risk of non-alcoholic fatty liver disease (NAFLD). The researchers conducted a systematic review and meta-analysis of observational studies and found that a higher intake of polyphenols was associated with a reduced risk of NAFLD. However, due to the limited number of studies available, further research is needed to confirm these findings and provide recommendations for increasing polyphenol intake in the general population. This study highlights the potential benefits of polyphenols in preventing NAFLD, a global health issue with increasing prevalence worldwide. [Extracted from the article]

Researchers from Golestan University of Medical Sciences in Gorgan, Iran have conducted a study on the prevalence of fatty liver in patients with inflammatory bowel disease (IBD) in relation to obesity. The study included 40 IBD patients and found that non-alcoholic fatty liver disease (NAFLD) was significantly associated with overweight and obesity among these patients. The researchers recommend screening IBD patients for risk factors associated with NAFLD to prevent liver disease. This study provides valuable insights into the epidemiological burden of NAFLD in IBD patients. [Extracted from the article]

A study conducted by researchers at Tabriz University of Medical Sciences in Iran explored the effects of myo-inositol supplementation on obese patients with non-alcoholic fatty liver disease (NAFLD). The study found that myo-inositol supplementation slightly activated the SIRT-1 pathway, which has anti-atherosclerotic properties. The researchers also observed improvements in cholesterol-related atherogenic indices and hematological parameters in the myo-inositol group. These findings suggest that myo-inositol supplementation may have potential benefits for obese patients with NAFLD. [Extracted from the article]

A recent study from Hospital Universitario in Seville, Spain, has highlighted the increasing prevalence of non-alcoholic fatty liver disease (NAFLD), which affects nearly 25% of the global population. NAFLD can progress from simple steatosis to non-alcoholic steatohepatitis, which can lead to cirrhosis and hepatocellular carcinoma. The study also found that patients with NAFLD are at an increased risk of cardiovascular disease (CVD), which is the leading cause of mortality in these patients. The research aims to explore the link between NAFLD and CVD, including the role of various factors such as proprotein convertase substilisin/kenin type 9, extracellular vesicles, microbiota, and genetic factors. [Extracted from the article]

A study conducted at Qena University Hospital in Egypt aimed to determine the prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in cardiovascular patients and identify risk factors contributing to its development. The study involved 100 cardiovascular patients and utilized various clinical, diagnostic, and laboratory methods. The findings revealed that NAFLD significantly increased in cardiac patients and was associated with factors such as sex, age, BMI, chronic diseases, obesity, hyperlipidemia, and heart diseases. This research provides valuable insights into the relationship between NAFLD and cardiovascular health. [Extracted from the article]

A clinical trial, NCT06402084, is currently recruiting participants to investigate the relationship between fatty liver and breast cancer. Non-alcoholic fatty liver disease (NAFLD) affects around 30% of the population and is characterized by fat accumulation in the liver. Breast cancer patients often develop NAFLD, which may lead to cardiovascular and insulin resistance complications. The trial aims to assess the lipid profile of breast cancer patients using abdominal ultrasound and lipid testing. The study is being conducted at Sohag University in Egypt and is seeking 100 female participants between the ages of 18 and 65. [Extracted from the article]

A new report from researchers at Central South University in China explores the association between non-alcoholic fatty liver disease (NAFLD) and sarcopenia. The study, which involved a systematic review and meta-analysis of observational clinical studies, found that individuals with NAFLD had a higher prevalence of sarcopenia compared to those without NAFLD. However, the association varied by region, with a significant correlation observed in the Asian group but not in the American and European groups. The findings provide a basis for understanding the relationship between NAFLD and sarcopenia and may inform strategies for managing sarcopenia in individuals with NAFLD. [Extracted from the article]

A recent study conducted in Yibin, People's Republic of China, investigated the effects of Paederia scandens on non-alcoholic fatty liver disease (NAFLD) in a rat model. The study found that dietary Paederia scandens significantly reduced levels of triglycerides, total cholesterol, glucose, and low-density lipoprotein cholesterol in the rats with NAFLD. Additionally, the treatment with Paederia scandens upregulated proteins involved in fatty acid beta oxidation, PPAR, and cytochrome P450 signaling pathways, suggesting its potential as an effective therapy for NAFLD. This research provides new insights into the treatment of NAFLD. [Extracted from the article]

A recent study conducted by Capital Medical University in Beijing, China, aimed to understand the impact of the diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD) and non-alcoholic fatty liver disease (NAFLD) on liver transplant recipients with hepatocellular carcinoma (HCC). The study found that the diagnosis of MAFLD was more strongly associated with metabolic abnormalities than the diagnosis of NAFLD. Factors such as tumor size, microvascular invasion, lack of tumor capsule, post-transplant MAFLD, and decreased post-transplant lymphocyte percentage were identified as risk factors for HCC recurrence. This research provides valuable insights into the prognosis and management of liver transplant recipients with HCC. [Extracted from the article]